个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共27条记录   Antibody Conjugate Therapeutics: Challenges and Potential [作者：Teicher, BA; Chari, RVJ,期刊：Clinical Cancer Research, 页码：6389-6397 , 文章类型： Article，,卷期：2011年17-20] Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The n... Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox [作者：Kreitman, RJ; Pastan, I,期刊：Clinical Cancer Research, 页码：6398-6405 , 文章类型： Article，,卷期：2011年17-20] Recombinant immunotoxins are fusion proteins that contain the cytotoxic portion of a protein toxin fused to the Fv portion of an antibody. The Fv binds to an antigen on a target cell and brings the toxin into the cell in... Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends [作者：Steiner, M; Neri, D,期刊：Clinical Cancer Research, 页码：6406-6416 , 文章类型： Article，,卷期：2011年17-20] When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not on... Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin [作者：Ricart, AD,期刊：Clinical Cancer Research, 页码：6417-6427 , 文章类型： Article，,卷期：2011年17-20] Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently sensitive to cytotoxic agents. CD33 and CD22 are specif... Brentuximab Vedotin (SGN-35) [作者：Katz, J; Janik, JE; Younes, A,期刊：Clinical Cancer Research, 页码：6428-6436 , 文章类型： Article，,卷期：2011年17-20] Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. SGN-35 consists of the cAC10 chimerized IgG1 monoclonal... Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer [作者：LoRusso, PM; Weiss, D; Guardino, E; Girish, S; Sliwkowski, MX,期刊：Clinical Cancer Research, 页码：6437-6447 , 文章类型： Article，,卷期：2011年17-20] Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor (HER2)-targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of may... Therapeutic Oligonucleotides: The Road Not Taken [作者：Stein, CA; Goel, S,期刊：Clinical Cancer Research, 页码：6369-6372 , 文章类型： Editorial Material，,卷期：2011年17-20] Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep l... The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression [作者：Hedley, BD; Allan, AL; Xenocostas, A,期刊：Clinical Cancer Research, 页码：6373-6380 , 文章类型： Article，,卷期：2011年17-20] Over the past few decades, understanding of the physiologic function of erythropoietin (EPO) has evolved significantly. EPO binds to erythropoietin receptors (EPOR), initiating signaling that stimulates growth, inhibits ... TLX1-Induced T-cell Acute Lymphoblastic Leukemia [作者：De Keersmaecker, K; Ferrando, AA,期刊：Clinical Cancer Research, 页码：6381-6386 , 文章类型： Article，,卷期：2011年17-20] The TLX1 transcription factor oncogene is frequently activated by chromosomal translocations in T-cell acute lymphoblastic leukemia (T-ALL) and defines a distinct molecular group of tumors characterized by differentiatio... Antibody Conjugates: The Future Is Now [作者：Bates, SE,期刊：Clinical Cancer Research, 页码：6388-6388 , 文章类型： Editorial Material，,卷期：2011年17-20] SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies [作者：Blanc, V; Bousseau, A; Caron, A; Carrez, C; Lutz, RJ; Lambert, JM,期刊：Clinical Cancer Research, 页码：6448-6458 , 文章类型： Article，,卷期：2011年17-20] SAR3419 is a novel anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivate through a cleavable linker for the treatment of B-cell malignancies. SAR3419 combines the strengths of a high-potency tubulin... Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC [作者：Medema, RH; Lin, CC; Yang, JCH,期刊：Clinical Cancer Research, 页码：6459-6466 , 文章类型： Review，,卷期：2011年17-20] Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are ... Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism [作者：Twitty, CG; Jensen, SM; Hu, HM; Fox, BA,期刊：Clinical Cancer Research, 页码：6467-6481 , 文章类型： Article，,卷期：2011年17-20] Purpose: Tumor-specific antigens of 3-methylcholanthrene (MCA)-induced sarcomas were defined by the narrow immune responses they elicited, which uniquely rejected the homologous tumor, with no cross-reactions between ind... Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer [作者：Jin, N; Jiang, TY; Rosen, DM; Nelkin, BD; Ball, DW,期刊：Clinical Cancer Research, 页码：6482-6489 , 文章类型： Article，,卷期：2011年17-20] Purpose: In thyroid cancer clinical trials, agents targeting VEGF receptors (VEGFR) and RET, among other kinases, have led to partial responses but few complete or durable responses. The RAF-MEK-ERK and PI3K-AKT-mTOR sig... The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization [作者：Sekhar, KR; Reddy, YT; Reddy, PN; Crooks, PA; Venkateswaran, A; McDonald, WH; Geng, L; Sasi, S; Van Der Waal, RP; Roti, JLR; Salleng, KJ; Rachakonda, G; Freeman, ML,期刊：Clinical Cancer Research, 页码：6490-6499 , 文章类型： Article，,卷期：2011年17-20] Purpose: Radiation therapy continues to be an important therapeutic strategy for providing definitive local/regional control of human cancer. However, oncogenes that harbor driver mutations and/or amplifications can comp... Significant Biological Role of Sp1 Transactivation in Multiple Myeloma [作者：Fulciniti, M; Amin, S; Nanjappa, P; Rodig, S; Prabhala, R; Li, C; Minvielle, S; Tai, YT; Tassone, P; Avet-Loiseau, H; Hideshima, T; Anderson, KC; Munshi, NC,期刊：Clinical Cancer Research, 页码：6500-6509 , 文章类型： Article，,卷期：2011年17-20] Purpose: The transcription factor specificity protein 1 (Sp1) controls number of cellular processes by regulating the expression of critical cell cycle, differentiation, and apoptosis-related genes containing proximal GC...